- Home
- EWTX vs CET Comparison
EWTX vs CET Comparison
Compare EWTX & CET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWTX
- CET
- Stock Information
- Founded
- EWTX 2017
- CET 1929
- Country
- EWTX United States
- CET United States
- Employees
- EWTX N/A
- CET N/A
- Industry
- EWTX Biotechnology: Pharmaceutical Preparations
- CET Finance/Investors Services
- Sector
- EWTX Health Care
- CET Finance
- Exchange
- EWTX Nasdaq
- CET Nasdaq
- Market Cap
- EWTX 1.5B
- CET 1.4B
- IPO Year
- EWTX 2021
- CET N/A
- Fundamental
- Price
- EWTX $14.06
- CET $50.78
- Analyst Decision
- EWTX Buy
- CET
- Analyst Count
- EWTX 9
- CET 0
- Target Price
- EWTX $39.89
- CET N/A
- AVG Volume (30 Days)
- EWTX 804.3K
- CET 20.8K
- Earning Date
- EWTX 11-06-2025
- CET 01-01-0001
- Dividend Yield
- EWTX N/A
- CET 4.53%
- EPS Growth
- EWTX N/A
- CET N/A
- EPS
- EWTX N/A
- CET 7.40
- Revenue
- EWTX N/A
- CET $27,062,484.00
- Revenue This Year
- EWTX N/A
- CET N/A
- Revenue Next Year
- EWTX N/A
- CET N/A
- P/E Ratio
- EWTX N/A
- CET $6.84
- Revenue Growth
- EWTX N/A
- CET 15.78
- 52 Week Low
- EWTX $10.60
- CET $40.24
- 52 Week High
- EWTX $38.12
- CET $51.16
- Technical
- Relative Strength Index (RSI)
- EWTX 46.82
- CET 68.63
- Support Level
- EWTX $13.69
- CET $50.09
- Resistance Level
- EWTX $15.16
- CET $51.16
- Average True Range (ATR)
- EWTX 0.68
- CET 0.60
- MACD
- EWTX -0.11
- CET 0.01
- Stochastic Oscillator
- EWTX 17.81
- CET 77.11
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
About CET Central Securities Corporation
Central Securities Corp is a non-diversified closed-end management investment company. Its investment objective is long-term growth of capital. The company invests in common stocks, bonds, convertible bonds, preferred stocks, convertible preferred stocks, warrants, options real estate, or short-term obligations of governments, banks, and corporations.